Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults With Progressive Systemic Sclerosis

Next Previous
Trial Profile

A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults With Progressive Systemic Sclerosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avenciguat (Primary)
  • Indications Diffuse scleroderma
  • Focus Therapeutic Use
  • Acronyms VITALISScE
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 03 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 26 Nov 2024 Planned primary completion date changed from 31 Oct 2025 to 22 Oct 2025.
  • 08 Aug 2023 Planned End Date changed from 27 May 2025 to 28 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top